Table 2.
Large trials having evalauted the tolerability and efficacy of lercanidipine therapy in daily clinical practice
| Study (year)a | n | Type | Medication | Duration | Peripheral edema (%) |
|---|---|---|---|---|---|
| LAURA study 2006 | 3175 | Open label, non-comparative | Lercanidipine 10–20 mg/day | 6 months | 5.1 |
| TOLERANCE study 2008 | 650 | Observational | Lercanidipine 20 mg vs amlodipine 10 mg or nifedipine GITS 60 mg | 2 months | 39.7 vs 57.3 |
| Burnier 2007 | 2199 | Observational, non-interventional | Lercanidipine 10 mg/20 mg; mono, step on, or substitution therapy | 2 months | 0.6–3 |
| ELYPSE 2002 | 9059 | Observational | Lercanidipine 10 mg | 3 months | 1.2 |
| COHORT 2002 | 828 | Prospective, randomized, double blind | Lercanidipine 10 mg vs amlodipine 5 mg vs lacidipine 2 mg | 12 months | 9 vs 19 vs 4 |
a
Studies were selected by performing a Pubmed query with “lercanidipine”, “adherence”, “compliance” and “tolerability” as search terms.